Caris Life Sciences, Inc. (CAI) stock intrinsic value fair value estimate & owner earnings analysis

Caris Life Sciences runs a molecular profiling business for cancer care: physicians send a tumor tissue sample (its MI Profile platform) or a blood draw (its newer Caris Assure test) to the company's lab, and Caris returns a genomic report that helps oncologists choose therapy. It also sells profiling data and services to biopharma companies, and is preparing to launch a blood-based early cancer detection test, Caris Detect, in 2026. The company completed its initial public offering on the Nasdaq (symbol CAI) in June 2025. 2025 was a turning point. Revenue rose 97%, to $812 million from $412 million in 2024, operating income turned positive for the first time ($45 million), and cash flow from operations swung from a $245 million outflow to an $83 million inflow. That improvement continued into 2026: for the first half of the year, revenue was up 59% year over year and net income was within about $1 million of breakeven. It's worth understanding what drove 2025's jump, because it shapes how we think about what comes next: the company's own figures show that about three-quarters of the increase came from higher pricing and a richer payer mix, tied mainly to a newly expanded test (MI Cancer Seek) gaining full Medicare coverage during the year, while the actual number of tests performed grew a more modest 16%. A pricing and coverage step-up of that size does not repeat every year, so we have not projected the 97% pace forward. To estimate what the shares are worth, we start from cash actually generated by the business, remove the swings caused by the timing of receivables, supplies, and payables (which can make one year's cash flow look better or worse than the business's real earning power), subtract stock-based compensation as a real cost even though it doesn't use cash, and subtract only the spending needed to maintain existing lab capacity rather than the spending aimed at growth. On that basis, 2025 (the company's first full year with a normalized, cash-generating profile) produced roughly $38 million of owner earnings, or about $0.13 per share on the 283 million shares now outstanding. We use 2025 alone as the starting point rather than averaging in 2023 or 2024, because those years describe a company that was still years from breakeven, funded very differently (through venture and private capital, on a share count roughly one-eighth of today's), and gaining full Medicare pricing on its core test had not yet happened. Every future year's cash flow is discounted back at a flat 6% rate, roughly the long-term government bond yield plus a small margin; we do not adjust that rate up or down for how risky a given company looks; instead all of the risk judgment is expressed in the spread between the three cases below. The base case assumes the 2025 pricing and coverage gains hold, and that growth continues from levers that are already visible and running: Caris Assure's case volume grew from about 16,000 to 29,000 tests in a single year and has room to keep scaling; the company's second-largest payer grew from 14% to 21% of revenue in one year, showing broader adoption beyond Medicare is already underway. Growth starts around a third in the first year and steadily decelerates to high single digits by year ten as the business matures. Beyond year ten, we don't assume further compounding without something specific to point to, so we hold that year's earning level flat rather than grow it further -- but we don't fade it to zero either, because the durability of national Medicare coverage for the company's core test and its embedded base of referring oncologists and hospital systems are real, structural features of the business today. On these assumptions, the shares are worth about $9.45 today. The bear case centers on two concrete risks visible in the filings. First, payer concentration: the largest single payer (Medicare) accounted for 37% of 2025 revenue and has been rising, and the top two payers together made up nearly 60% of revenue. Second, coverage durability differs by test -- the flagship MI Cancer Seek test carries a national Medicare coverage decision, but Caris Assure and another tissue test are covered only under a regional Medicare coverage policy that can be revised at the regional contractor's discretion, and separately, federal law caps how much Medicare's lab fee schedule can be cut each year at 0% in 2026 but as much as 15% per test per year from 2027 through 2029, with a new pricing data cycle starting in 2026. We also note that the company's biopharma-services revenue, a smaller segment, shrank 28% in 2025, and that Caris competes against much larger, well-capitalized rivals including Roche's Foundation Medicine, Tempus, Guardant Health, and Natera. The bear case assumes a reimbursement reset lands around 2027-2028, stalling growth for a couple of years before slower, volume-only growth resumes. On these assumptions, the shares are worth about $3.04. The bull case assumes the same already-visible levers simply execute well: Caris Assure's nearly 80% volume growth continues for longer, commercial-payer adoption keeps broadening at the pace already shown in 2025, and stock-based compensation (still about 8% of revenue) keeps shrinking as a share of a larger revenue base. On these assumptions, the shares are worth about $18.04. We have deliberately left Caris Detect, the 2026 early-detection launch, out of all three cases -- there's no contracted revenue or track record yet to size it, so it is better thought of as an option on top of this valuation than a case input. Given the width of that range, only about one year of proven, normalized profitability as a public company, and a meaningful share of revenue resting on Medicare pricing decisions that can move on a known schedule, the margin-of-safety price sits at a substantial discount to the $9.45 base estimate -- around $5.20 a share -- to leave room for being wrong. A note on what changed from the prior write-up: that analysis leaned on trailing twelve-month cash flow and used a different, higher discount rate for each case to reflect risk. This update instead anchors on the last full fiscal year (trailing-twelve-month figures move too much quarter to quarter to anchor on reliably), explicitly strips out working-capital timing swings from the cash flow, and applies one fixed discount rate to every case, moving all of the risk judgment into the spread between the bear and bull cases instead. That shift in method, more than any change in the business itself, is the main reason the estimated value differs from the prior write-up -- the underlying financial trend (accelerating revenue, narrowing losses, cash flow now solidly positive) has in fact continued to improve.